Ronac Mamtani, MD, MSCE

faculty photo
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horwitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med 29(11), Nov 2023.

Bange EM, Li Y, Kumar P, Doucette A, Gabriel P, Parikh R, Li EH, Mamtani R*, Getz KD*.: The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer. Cancer 10.1002/cncr.35116., Nov 21 2023.

Boursi B, Wileyto EP, Mamtani R, Domchek SM, Golan T, Hood R, Reiss KA.: Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival. JAMA Netw Open Nov 2023.

Doshi GK, Li H, Burcu M, Annavarapu S, Wells K, Imai K, Moreno BH, Singhal P, Mamtani R.: Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma. Front Oncol Oct 2023.

Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME.: Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens. Clin Lung Cancer 24(6), Sept 2023.

Shah M, Mamtani R, Marmarelis ME, Hennessy S: Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90. Clin Lung Cancer 24(3), May 2023.

Mamtani R, Zhang H, Parikh RB, Patel K, Li H, Imai K, Hubbard RA: Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer. JAMA Netw Open 6(4), April 2023.

Vader DT, Mamtani R, Li Y, Griffith SD, Calip GS, Hubbard RA.: Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation. Epidemiology Page: doi: 10.1097/EDE.0000000000001618, April 2023.

Brown TJ, Mamtani R, Gimotty PA, Karasic TB, Yang YX: Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. J Cancer Res Clin Oncol 149(6), Mar 2023.

Parikh RB, Hubbard RA, Wang E, Royce TJ, Cohen AB, Clark AS, Mamtani R: Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval. JAMA Oncol Page: doi: 10.1001/jamaoncol.2022.7770, Feb 2023.

back to top
Last updated: 11/29/2023
The Trustees of the University of Pennsylvania